American Journal of Perinatology Publishes Results of Group B Streptococcus Research Using NanoLogix Biotechnology
August 08 2011 - 5:00AM
Business Wire
NanoLogix (OTC MARKETS: NNLX), a biotechnology innovator in the
rapid detection and identification of live-cell bacteria and
microorganisms, announced today that the American Journal of
Perinatology has published a peer-reviewed paper from the
University of Texas Health Science Center - Houston confirming
NanoLogix BioNanoPore (BNP) and BioNanoFilter (BNF) Quick Test
technology detect and identify Group B Strep in four to six hours.
The published results are in stark contrast to current Petri
culturing or PCR Protocol (DNA sequencing) methods. While those
conventional methods require between 48 to 72 hours of incubation
to obtain results, the NanoLogix diagnostic technology for Group B
Strep has proven to be 12 to 18 times faster.
The American Journal of Perinatology is an international,
peer-reviewed, and indexed journal publishing 10 issues a year
dealing with original research and topical reviews. It is the
definitive forum for specialists in obstetrics, neonatology,
perinatology, and maternal/fetal medicine, with emphasis on
bridging the different fields. The journal abstract can be found
at:
https://www.thieme-connect.com/ejournals/abstract/ajp/doi/10.1055/s-0031-1285099.
Registration is required to access the full text of the journal
article.
“We continue to be amazed at both the consistency and
reliability of this NanoLogix technology,” said Jonathan Faro,
M.D., Ph.D., Assistant Professor in General Obstetrics &
Gynecology at UTHSC - Houston and lead author of the study. “It is
very rewarding to see basic science research apply so fluidly to
the clinic and office setting. We consider ourselves very lucky to
be involved with studying the application of the NanoLogix BNP and
BNF Quick Tests as they apply to Group B Streptococcus. This
validation is just a very large tip of an incredibly enormous
iceberg, and we are anxious to study this technology with
additional organisms and in new and creative applications.”
According to the Centers for Disease Control (CDC), 25% of
pregnant women may be colonized with Group B Strep. If colonized
mothers give birth before antibiotics can be administered, the
bacteria can be passed to the newborn and cause life-threatening
blood infections, such as meningitis, sepsis, pneumonia, or even
stillbirth. The U.S. CDC and World Health Organization (WHO)
recommend all pregnant women worldwide be tested for Group B Strep
between 35 and 37 weeks.
The rapid diagnostic tests from NanoLogix will benefit pregnant
women who are deemed “at risk” for colonization of GBS at the time
of delivery. With the need to wait only four hours for test results
using NanoLogix test kits, physicians will have the opportunity to
make more rapid decisions about administering bacteria-specific
antibiotics to patients. With this breakthrough, it will be
possible to reduce the over-use of broad-spectrum antibiotics that
contribute to the ever-increasing problem of antibiotic
resistance.
“We are thrilled with the results of the research conducted at
UTHSC - Houston and we thank Dr. Faro and the other physicians for
their work,” said NanoLogix CEO Bret Barnhizer. “This verification
of the effectiveness of our BNP and BNF Quick Test technology
should soon benefit countless women and newborns around the world.
Once FDA approved and adopted, patients diagnosed with Group B
Strep can receive rapid and specific antibiotic treatment, while
many others will avoid treatment altogether as a direct result of
the UTHSC research. With over 125 million births annually around
the world, and 4 million births in the US alone, the potential
market for a rapid, inexpensive, sensitive Group B Strep test is
vast.”
Both Nanologix BNP and BNF Quick Test kits were validated in the
study for Group B Strep detection and identification. They are easy
to use and require little training and minimal equipment (other
than an incubator). This allows the tests to be administered in
remote areas with limited resources and personnel. Additionally,
the tests can be performed on a single specimen – which is not cost
effective for PCR-related methods.
Findings of the study, along with Group B Strep data isolated
directly from patient samples will be presented at the 78th annual
meeting of the Central Association of Obstetricians and
Gynecologists October 26-28, 2011.
This UTHSC - Houston study published in the American Journal of
Perinatology is the first of several peer-reviewed research papers
on NanoLogix technology to be published between now and early
2012.
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on rapid
diagnostics. Its products offer accelerated detection and
identification of microorganisms. In addition to medical and
homeland security applications, NanoLogix technology is applicable
in pharmaceutical, industrial, veterinary and environmental
testing. Patents granted to NanoLogix can be used in the areas of
applied microbiology, soil microbiology and bioremediation,
microbial physiology, molecular biology, pharmacology,
pharmaco-kinetics, and antibiotic sensitivity. For more information
visit www.nanologix.com.
This press release contains statements, which may constitute
"forward- looking statements" within the meaning of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended by
the Private Securities Litigation Reform Act of 1995. Those
statements include statements regarding the intent, belief or
current expectations of NanoLogix, Inc., and members of its
management as well as the assumptions on which such statements are
based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, and that actual results may
differ materially from those contemplated by such forward-looking
statements. The Company undertakes no obligation to update or
revise forward-looking statements to reflect changed assumptions,
the occurrence of unanticipated events or changes to future
operating results.
NanoLogix (CE) (USOTC:NNLX)
Historical Stock Chart
From Jun 2024 to Jul 2024
NanoLogix (CE) (USOTC:NNLX)
Historical Stock Chart
From Jul 2023 to Jul 2024